Cronos Group (CRON) Projected to Release Quarterly Earnings on Thursday

Cronos Group (NASDAQ:CRON) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $0.01 per share and revenue of $44.20 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Cronos Group (NASDAQ:CRON) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. The business had revenue of $45.21 million during the quarter, compared to analyst estimates of $42.20 million. Cronos Group had a negative net margin of 1.14% and a negative return on equity of 1.26%.

Cronos Group Stock Performance

Shares of CRON stock opened at $2.83 on Tuesday. Cronos Group has a fifty-two week low of $1.93 and a fifty-two week high of $3.43. The company has a 50 day moving average price of $2.77 and a 200 day moving average price of $2.67. The stock has a market capitalization of $1.06 billion, a P/E ratio of 283.28 and a beta of 0.90.

Wall Street Analysts Forecast Growth

CRON has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Cronos Group in a research report on Friday, May 29th. Wall Street Zen raised Cronos Group from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, TD Securities reiterated a “buy” rating on shares of Cronos Group in a research note on Tuesday, May 12th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Cronos Group has a consensus rating of “Hold” and an average target price of $2.30.

Institutional Trading of Cronos Group

Large investors have recently made changes to their positions in the company. Brooklyn Investment Group lifted its stake in Cronos Group by 5,733.0% in the third quarter. Brooklyn Investment Group now owns 10,966 shares of the company’s stock worth $30,000 after acquiring an additional 10,778 shares during the last quarter. Scientech Research LLC acquired a new position in Cronos Group during the 3rd quarter worth approximately $32,000. Sender Co & Partners Inc. purchased a new stake in shares of Cronos Group in the 3rd quarter valued at approximately $35,000. HighTower Advisors LLC increased its position in shares of Cronos Group by 323.4% in the 4th quarter. HighTower Advisors LLC now owns 12,959 shares of the company’s stock valued at $34,000 after purchasing an additional 18,761 shares during the last quarter. Finally, Jump Financial LLC acquired a new stake in shares of Cronos Group in the 4th quarter valued at $42,000. 8.71% of the stock is currently owned by hedge funds and other institutional investors.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.